Cancer Australia

Entity resources and planned performance

# Cancer Australia

[Section 1: Entity overview and resources 258](#_Toc134113480)

[1.1 Strategic direction statement 258](#_Toc134113481)

[1.2 Entity resource statement 259](#_Toc134113482)

[1.3 Budget measures 261](#_Toc134113483)

[Section 2: Outcomes and planned performance 262](#_Toc134113484)

[2.1 Budgeted expenses and performance 262](#_Toc134113485)

[Section 3: Budgeted financial statements 268](#_Toc134113486)

[3.1 Budgeted financial statements 268](#_Toc134113487)

[3.2 Budgeted financial statements tables 269](#_Toc134113488)

## Section 1: Entity overview and resources

### 1.1 Strategic direction statement[[1]](#footnote-1)

As the Australian Government’s national cancer control agency, Cancer Australia aims to reduce the impact of cancer, address disparities, and improve outcomes for people affected by cancer. The Australian Government, through Cancer Australia:

* provides national leadership in cancer control
* coordinates evidence‑informed approaches with a range of healthcare providers and groups across the continuum of care
* leads the development of sustainable and effective models of cancer care
* oversees a dedicated budget for cancer research, supports clinical trial capacity and strengthens national data capacity
* provides advice on appropriate cancer care.

To achieve its aims in 2023–24, Cancer Australia will use an evidence-based approach and collaboratively engage with stakeholders to:

* drive implementation of the Australian Cancer Plan to improve outcomes for all Australians affected by cancer
* work with First Nations leaders to co-design and deliver improved cancer care for First Nations peoples
* interpret evidence to inform development and implementation of policies and programs in cancer control
* fund cancer research in areas of identified priority
* support industry independent cancer clinical trials groups
* drive efforts to strengthen national data capacity
* provide evidence-based information and resources for consumers, health professionals and the community.

The role and functions of Cancer Australia are set out in the *Cancer Australia Act 2006*. Cancer Australia is subject to the *Public Service Act 1999* and the *Auditor‑General Act 1997*, and is a non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013*.

### 1.2 Entity resource statement

Table 1.1 shows the total funding from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity’s operations) classification.

For more detailed information on special accounts and special appropriations, refer to *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (that is, appropriations/cash available) basis, whilst the ‛Budgeted expenses by Outcome’ tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis.

#### Changes to indexation framework for various programs

The indexation framework for programs indexed by Wage Cost Indices, including for government supported services, has been updated to better align with wages and prices movements.

Increased funding has been provided to the following program:

Program 1.1: Improved Cancer Control

Table 1.1: Cancer Australia resource statement – Budget estimates for
2023–24 as at Budget May 2023

|  |  |  |
| --- | --- | --- |
|  | **2022–23 Estimated actual$'000** | **2023–24Estimate$'000** |
| **DEPARTMENTAL** |  |   |
| Prior year appropriation available | 7,873 | 3,011 |
| **Annual appropriations** |  |  |
| Ordinary annual services (a) |  |  |
| Departmental appropriation | 11,077 | 13,323 |
| s74 retained revenue receipts (b) | 2,199 | 1,671 |
| Departmental Capital Budget (c) | 83 | 84 |
| Other services (d) |  |   |
| Equity injection | - | - |
| **Total departmental annual appropriations** | **13,359** | **15,078** |
| **Total departmental resourcing** | **21,232** | **18,089** |
| **ADMINISTERED** |  |   |
| Prior year appropriation available | 3,575 | 3,575 |
| **Annual appropriations** |  |   |
| Ordinary annual services (a) |  |   |
| Outcome 1 | 18,623 | 24,743 |
| Other services (d) |  |   |
| Administered assets and liabilities | - | - |
| **Total administered annual appropriations** | **18,623** | **24,743** |
| **Total administered resourcing**  | **22,198** | **28,318** |
| **Total resourcing for Cancer Australia** | **43,430** | **46,407** |
|  |  |  |
|   | **2022–23** | **2023–24** |
| **Average staffing level (number)** | 71 | 79 |

All figures are GST exclusive.

(a) Appropriation Bill (No. 1) 2023–24.

(b) Estimated retained revenue receipts under section 74 of the *Public Governance, Performance and Accountability Act 2013* (PGPA Act).

(c) Departmental Capital Budgets are not separately identified in Appropriation Bill (No. 1) and form part of ordinary annual services items. Please refer to Table 3.5 within this chapter for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

(d) Appropriation Bill (No. 2) 2023–24.

### 1.3 Budget measures

Budget measures in Part 1 relating to the Cancer Australia are detailed in *Budget Paper No. 2* and are summarised below.

Table 1.2: Cancer Australia 2023–24 Budget measures

Part 1: Measures announced since the 2022–23 October Budget

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|   | Program | **2022–23 $'000** | **2023–24 $'000** | **2024–25 $'000** | **2025–26 $'000** | **2026–27 $'000** |
| **Improving Health Outcomes for Aboriginal and Torres Strait Islander people (a)** |
| Cancer Australia | 1.1 |  |  |  |  |  |
| Departmental payments |  | - | 970 | 1,453 | 1,370 | 1,427 |
| Administered payments |  |  | 1,239 | 10,039 | 11,300 | 10,790 |
| **Total payments** |  | **-** | **2,209** | **11,492** | **12,670** | **12,217** |
| **Vaping Regulation Reform and Smoking Cessation Package (a)** |
| Cancer Australia | 1.1 |  |  |  |  |  |
| Departmental payments |  | - | 922 | 934 | 156 | 158 |
| Administered payments |  |  | 4,190 | 4,391 | 1,607 | 1,821 |
| **Total payments** |   | **-** | **5,112** | **5,325** | **1,763** | **1,979** |

Prepared on a Government Financial Statistics (Underlying Cash) basis. Figures displayed as a negative (-) represent a decrease in funds and a positive (+) represent an increase in funds.

 (a) Cancer Australia is not the lead entity for these measures. Cancer Australia impacts only are shown in this table.

## Section 2: Outcomes and planned performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which government entities achieve the intended results of their outcome statements. Entities are required to identify the programs which contribute to government outcomes over the Budget and forward years.

Each outcome is described below together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

**Note:**

Performance reporting requirements in the Portfolio Budget Statements are part of the Commonwealth Performance Framework established by *the Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance measures described in Portfolio Budget Statements will be read with broader information provided in an entity’s Corporate Plan and Annual Performance Statement – included in Annual Reports – to provide an entity’s complete performance story.

Cancer Australia’s most recent Corporate Plan and Annual Performance Statement are available at: www.canceraustralia.gov.au/about-us/accountability-and-reporting

### 2.1 Budgeted expenses and performance

**Outcome 1**

Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support.

#### Program contributing to Outcome 1

**Program 1.1: Improved Cancer Control**

#### Linked programs

| Other Commonwealth entities that contribute to Outcome 1 |
| --- |
| Department of Health and Aged Care |
| Program 1.1: Health Research, Coordination and AccessThe Department of Health and Aged Care has responsibility for health and medical research through the Medical Research Future Fund, which will support the sustainability of the health system into the future and drive further medical innovation.Program 1.5: Preventive Health and Chronic Disease SupportThe Department of Health and Aged Care has policy responsibility for improving the detection, treatment and survival outcomes for people with cancer. This includes oversight of cancer screening programs, such as the National Bowel Cancer Screening Program, the BreastScreen Australia Program and the National Cervical Screening Program. |

*Budgeted expenses for Outcome 1*

This table shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by Administered and Departmental funding sources.

Table 2.1.1: Budgeted expenses for Outcome 1

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2022–23 Estimated actual$'000** | **2023–24Budget$'000** | **2024–25Forward estimate$'000** | **2025–26Forward estimate$'000** | **2026–27Forward estimate$'000** |
| **Program 1.1: Improved Cancer Control** |
| Administered expenses |  |   |  |  |  |
| Ordinary annual services (a) | 18,623 | 24,743 | 34,362 | 33,297 | 33,388 |
| Departmental expenses |  |   |  |  |  |
| Departmental appropriation (b) | 13,276 | 14,994 | 14,449 | 13,734 | 14,057 |
| Expenses not requiring appropriation in the Budget year (c) | 542 | 434 | 328 | 221 | 196 |
| Operating deficit (surplus) | 4,678 | 500 | - | - | - |
| **Total for Program 1.1** | **37,119** | **40,671** | **49,139** | **47,252** | **47,641** |
| **Total expenses for Outcome 1** | **37,119** | **40,671** | **49,139** | **47,252** | **47,641** |
|  |  |  |  |  |  |
|   | **2022–23** | **2023–24** |  |  |  |
| **Average staffing level (number)** | 71 | 79 |  |  |  |

(a) Appropriation Bill (No. 1) 2023–24.

(b) Departmental appropriation combines 'Ordinary annual services Appropriation Bill (No. 1)' and 'Revenue from independent sources (s74)'.

(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expenses and audit fees, interest on RoU (Right-of-Use asset) and credit applied to rental supplier expenses (rental payments).

**Performance measures for Outcome 1**

Table 2.1.2 details the performance measures for each program associated with Outcome 1. It also provides the related key activities as expressed in the current corporate plan where further detail is provided about the delivery of the activities related to the program, the context in which these activities are delivered and how the performance of these activities will be measured. Where relevant, details of the 2023–24 Budget measures that have created new programs or materially changed existing programs are provided.

Table 2.1.2: Performance measures for Cancer Australia

|  |
| --- |
| Outcome 1 |
| Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support. |
| Program Objective – Program 1.1: Improved Cancer Control |
| Provide national leadership in cancer control across the care continuum to reduce the impact of cancer, address disparities, and improve outcomes for people affected by cancer through the development and promotion of evidence-based practice, funding cancer research, and providing consumers and health professionals with cancer information and resources. |
| Key Activities |
| * Provide national leadership in cancer control.
* Develop and promote evidence-based best practice cancer care.
* Fund cancer research and drive efforts to strengthen national data capacity in consultation with relevant agencies.
* Provide consumer and health professional cancer information and resources.
 |
| Performance Measures |
| Lead the implementation of the Australian Cancer Plan (the Plan), which sets out national priorities and action areas over the next 10 years to improve outcomes for all Australians affected by cancer. |
| Current Year2022–23 Expected Performance Results | Budget Year2023–24 Planned Performance Results | Forward Estimates2024–27 Planned Performance Results |
| Engagement and consultation with stakeholders across the cancer control continuum in the development of the Plan.Approaches in the Plan addressed disparities in outcomes for all Australians affected by cancer.Delivered the Plan to the Minister for Health and Aged Care by April 2023. | Engage with the cancer sector to communicate and promote uptake of the Plan’s objectives, goals and ambitions. Develop a monitoring and evaluation framework that will capture sector wide activities to achieve the Plan’s objectives, goals and ambitions. Progress activities to achieve priority 2 year actions in the Plan.  | Evaluate the sector’s progress of the Plan’s 2 year actions**.** |
| Lead delivery of 5 early implementation National Pancreatic Cancer Roadmap priorities to improve the timely detection, management and care of people affected by pancreatic cancer. |
| Current Year2022–23 Expected Performance Results | Budget Year2023–24 Planned Performance Results | Forward Estimates2024–27 Planned Performance Results |
| Collaboratively engaged with key stakeholders in developing First Nations led culturally responsive models of pancreatic cancer care. Commenced delivery of the 5 early implementation Roadmap priorities funded by the Department of Health and Aged Care. | Engage collaboratively with key stakeholders in developing First Nations led culturally responsive models of pancreatic cancer care. Deliver 5 early implementation Roadmap priorities funded by the Department of Health and Aged Care. | N/A. |

|  |
| --- |
| Work with First Nations leaders to co-design and deliver improved cancer care for First Nations peoples. |
| Current Year2022–23 Expected Performance Results | Budget Year2023–24 Planned Performance Results | Forward Estimates2024–27 Planned Performance Results |
| Progressed priority initiatives in alignment with the *National Aboriginal and Torres Strait Islander Cancer Framework* for First Nations peoples with cancer in collaboration with key stakeholders, with positive feedback from Australia’s Leadership Group on Aboriginal and Torres Strait Islander Cancer. | Priority First Nations cancer control initiatives led and co-designed by First Nations partners. | As per 2023–24. |
| Provide evidence-based cancer information to cancer consumers, health professionals and the community. |
| Current Year2022–23 Expected Performance Results | Budget Year2023–24 Planned Performance Results | Forward Estimates2024–27 Planned Performance Results |
| Up to date evidence-based cancer information was made available on the Cancer Australia website. | Up to date evidence-based cancer information available on the Cancer Australia website.≥5 cancer information topics are reviewed and updated. | As per 2023–24. |
| Analyse, interpret and translate evidence to inform best practice cancer care. |
| Current Year2022–23 Expected Performance Results | Budget Year2023–24 Planned Performance Results | Forward Estimates2024–27 Planned Performance Results |
| Research was translated into evidence-based information to assist and inform policy cancer care.Develop a cancer-specific genomics policy framework.Scoping and feasibility work completed to inform key design elements of a lung cancer screening program. | Translate research into evidence-based information to assist and inform policy cancer care.Develop a cancer-specific genomics policy framework. | Translate research into evidence-based information to assist and inform policy cancer care.Deliver a National Framework of Genomics in Cancer Control. |

|  |
| --- |
| **Fund priority cancer research through the *Priority-driven Collaborative Cancer Research Scheme.*** |
| Current Year2022–23 Expected Performance Results | Budget Year2023–24 Planned Performance Results | Forward Estimates2024–27 Planned Performance Results |
| Awarded ≥9 cancer research grants in areas of identified priority as per published grant guideline timeframes.MOUs were in place with a minimum of 4 national funding partners. | Award ≥6 cancer research grants in areas of identified priority as per published grant guideline timeframes.MOUs in place with a minimum of 4 national funding partners. | As per 2023–24. |
| **Provide high quality cancer data to inform national cancer control.** |
| Current Year2022–23 Expected Performance Results | **Budget Year2023–24 Planned Performance Results** | **Forward Estimates2024–27 Planned Performance Results** |
| Maintained published data analyses and insights on the National Cancer Control Indicators website. | Maintain published data analyses and insights on the National Cancer Control Indicators website. | As per 2023–24. |
| Material changes to Program 1.1 resulting from the following measures:There are no material changes to Program 1.1 resulting from measures. |

## Section 3: Budgeted financial statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2023–24 Budget year, including the impact of Budget measures and resourcing on financial statements.

### 3.1 Budgeted financial statements

#### 3.1.1 Differences between entity resourcing and financial statements

This section is not applicable to Cancer Australia.

#### 3.1.2 Explanatory notes and analysis of budgeted financial statements

##### **Departmental Resources**

###### **Comprehensive Income Statement**

This statement details budgeted financial results for Cancer Australia in 2023–24.

Cancer Australia has approved operating losses of $0.500 million in 2023–24, net of non-appropriated depreciation and amortisation expenses, depreciation and amortisation expenses for Right-of-Use asset and lease principal repayments. A break-even position is anticipated for the forward years.

Budget measures affecting the departmental appropriations are provided in Table 1.2.

###### **Balance Sheet**

Assets and liabilities, excluding Land and Buildings and lease liabilities, are anticipated to remain relatively stable across the forward years. There is an anticipated decrease in Land and Buildings and lease liabilities over the forward estimates.

###### **Cash Flow**

Cash flows are consistent with income, expenses and asset movements.

###### **Administered Resources**

Administered funding for Cancer Australia programs will continue in 2023–24. The level of administered funding across forward years represents Government expenditure on programs delivered to all Australians through Cancer Australia. Budget measures affecting the administered appropriations are provided in Table 1.2.

### 3.2 Budgeted financial statements tables

**Table 3.1: Comprehensive income statement (showing net cost of services) for the period ended 30 June**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | **2022–23 Estimated actual$'000** | **2023–24Budget$'000** | **2024–25Forward estimate$'000** | **2025–26Forward estimate$'000** | **2026–27Forward estimate$'000** |
| **EXPENSES** |  |   |   |   |   |
| Employee benefits | 12,265 | 11,459 | 11,722 | 11,064 | 11,337 |
| Supplier expenses | 4,116 | 2,591 | 1,898 | 1,803 | 1,815 |
| Grants expenses | 900 | 650 | - | - | - |
| Depreciation and amortisation | 1,189 | 1,192 | 1,129 | 1,067 | 1,089 |
| Interest on RoU | 22 | 32 | 24 | 17 | 8 |
| Other expenses | 4 | 4 | 4 | 4 | 4 |
| Write down and impairment of assets | - | - | - | - | - |
| **Total expenses** | **18,496** | **15,928** | **14,777** | **13,955** | **14,253** |
| **LESS:**  |  |  |  |  |  |
| **OWN-SOURCE INCOME** |  |  |  |  |  |
| **Revenue** |  |  |  |  |  |
| Other revenue | 2,199 | 1,671 | 329 | 312 | 330 |
| **Total revenue** | **2,199** | **1,671** | **329** | **312** | **330** |
| **Gains** |  |  |  |  |  |
| Other | 70 | 71 | 72 | 73 | 74 |
| **Total gains** | **70** | **71** | **72** | **73** | **74** |
| **Total own-source income** | **2,269** | **1,742** | **401** | **385** | **404** |
| **Net cost of (contribution by) services** | **16,227** | **14,186** | **14,376** | **13,570** | **13,849** |
| Revenue from Government | 11,077 | 13,323 | 14,120 | 13,422 | 13,727 |
| **Surplus (deficit)** | **(5,150)** | **(863)** | **(256)** | **(148)** | **(122)** |
| **Surplus (deficit) attributable to the Australian Government** | **(5,150)** | **(863)** | **(256)** | **(148)** | **(122)** |
| **OTHER COMPREHENSIVE INCOME** |  |  |  |  |  |
| Changes in asset revaluation reserves | - | - | - | - | - |
| **Total other comprehensive income**  | **-** | **-** | **-** | **-** | **-** |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(5,150)** | **(863)** | **(256)** | **(148)** | **(122)** |

**Table 3.1: Comprehensive income statement (showing net cost of services) for the period ended 30 June (continued)**

|  |
| --- |
| **Note: Impact of net cash appropriation arrangements** |
|  | **2022–23 Estimated actual$'000** | **2023–24Budget$'000** | **2024–25Forward estimate$'000** | **2025–26Forward estimate$'000** | **2026–27Forward estimate$'000** |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(5,150)** | **(863)** | **(256)** | **(148)** | **(122)** |
| plus non-appropriated expenses depreciation and amortisation expenses | 544 | 456 | 393 | 331 | 353 |
| plus depreciation and amortisation expenses for RoU | 645 | 736 | 736 | 736 | 736 |
| less lease principal repayments | (717) | (829) | (873) | (919) | (967) |
| **Total comprehensive income (loss) attributable to the agency** | **(4,678)** | **(500)** | **-** | **-** | **-** |

Prepared on Australian Accounting Standards basis.

RoU = Right-of-Use asset

**Table 3.2: Budgeted departmental balance sheet (as at 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | **2022–23 Estimated actual$'000** | **2023–24Budget$'000** | **2024–25Forward estimate$'000** | **2025–26Forward estimate$'000** | **2026–27Forward estimate$'000** |
| **ASSETS** |   |   |   |   |   |
| **Financial assets** |  |   |  |  |  |
| Cash and cash equivalents | 276 | 276 | 276 | 276 | 276 |
| Receivables | 3,104 | 2,596 | 2,588 | 2,391 | 2,316 |
| **Total financial assets** | **3,380** | **2,872** | **2,864** | **2,667** | **2,592** |
| **Non-financial assets** |  |   |  |  |  |
| Property, plant and equipment | 264 | 156 | 48 | 147 | 129 |
| Land and buildings | 3,852 | 2,944 | 2,036 | 1,128 | 220 |
| Intangibles | 186 | 102 | 82 | 106 | 104 |
| Other | 168 | 168 | 168 | 168 | 168 |
| **Total non-financial assets** | **4,470** | **3,370** | **2,334** | **1,549** | **621** |
| **Total assets** | **7,850** | **6,242** | **5,198** | **4,216** | **3,213** |
| **LIABILITIES** |  |   |  |  |  |
| **Payables** |  |   |  |  |  |
| Suppliers | 572 | 568 | 564 | 560 | 556 |
| Other payables | 13 | 13 | 13 | 13 | 13 |
| **Total payables** | **585** | **581** | **577** | **573** | **569** |
| **Interest bearing liabilities** |  |   |  |  |  |
| Leases | 3,828 | 2,999 | 2,126 | 1,207 | 240 |
| **Total interest bearing liabilities** | **3,828** | **2,999** | **2,126** | **1,207** | **240** |
| **Provisions** |  |   |  |  |  |
| Employees | 2,482 | 2,482 | 2,482 | 2,482 | 2,482 |
| Other provisions | 268 | 272 | 276 | 280 | 284 |
| **Total provisions** | **2,750** | **2,754** | **2,758** | **2,762** | **2,766** |
| **Total liabilities** | **7,163** | **6,334** | **5,461** | **4,542** | **3,575** |
| **Net assets** | **687** | **(92)** | **(263)** | **(326)** | **(362)** |
| **EQUITY** |  |   |  |  |  |
| Contributed equity | 1,641 | 1,725 | 1,810 | 1,895 | 1,981 |
| Reserves | - | - | - | - | - |
| Retained surpluses or (accumulated deficits) | (954) | (1,817) | (2,073) | (2,221) | (2,343) |
| **Total equity** | **687** | **(92)** | **(263)** | **(326)** | **(362)** |

Prepared on Australian Accounting Standards basis.

**Table 3.3: Departmental statement of changes in equity — summary of movement (Budget year 2023–24)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|   | **Retained earnings $'000** | **Asset revaluation reserve $'000** | **Contributed equity/capital $'000** | **Total equity $'000** |
| **Opening balance as at 1 July 2023** |  |  |  |  |
| Balance carried forward from previous period | (954) | - | 1,641 | **687** |
| Surplus (deficit) for the period | (863) | - | - | **(863)** |
| Capital budget - Bill 1 (DCB) | - | - | 84 | **84** |
| **Estimated closing balance as at30 June 2024** | **(1,817)** | **-** | **1,725** | **(92)** |

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

**Table 3.4: Budgeted departmental statement of cash flows (for the period ended 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | **2022–23 Estimated actual$'000** | **2023–24Budget$'000** | **2024–25Forward estimate$'000** | **2025–26Forward estimate$'000** | **2026–27Forward estimate$'000** |
| **OPERATING ACTIVITIES** |   |   |   |   |   |
| **Cash received** |  |   |  |  |  |
| Appropriations | 15,939 | 13,831 | 14,128 | 13,619 | 13,802 |
| Sale of goods and rendering of services | 2,199 | 1,671 | 329 | 312 | 330 |
| Net GST received | 186 | 186 | 186 | 186 | 186 |
| Other cash received | - | - | - | - | - |
| **Total cash received** | **18,324** | **15,688** | **14,643** | **14,117** | **14,318** |
| **Cash used** |  |   |  |  |  |
| Employees | 12,265 | 11,459 | 11,722 | 11,064 | 11,337 |
| Suppliers | 4,050 | 2,524 | 1,830 | 1,734 | 1,745 |
| Interest payments on lease liability | 22 | 32 | 24 | 17 | 8 |
| Grants | 900 | 650 | - | - | - |
| Net GST paid | 186 | 186 | 186 | 186 | 186 |
| Section 74 receipts transferred to the OPA | - | - | - | - | - |
| **Total cash used** | **17,423** | **14,851** | **13,762** | **13,001** | **13,276** |
| **Net cash from (or used by) operating activities** | **901** | **837** | **881** | **1,116** | **1,042** |
| **INVESTING ACTIVITIES** |  |   |  |  |  |
| **Cash used** |  |   |  |  |  |
| Purchase of property, plant and equipment and intangibles | 267 | 92 | 93 | 282 | 161 |
| **Total cash used** | **267** | **92** | **93** | **282** | **161** |
| **Net cash from (or used by) investing activities** | **(267)** | **(92)** | **(93)** | **(282)** | **(161)** |
| **FINANCING ACTIVITIES** |  |   |  |  |  |
| **Cash received** |  |   |  |  |  |
| Capital budget - Bill 1 (DCB) | 83 | 84 | 85 | 85 | 86 |
| **Total cash received** | **83** | **84** | **85** | **85** | **86** |
| **Cash used** |  |  |  |  |  |
| Lease principal repayments | 717 | 829 | 873 | 919 | 967 |
| **Total cash used** | **717** | **829** | **873** | **919** | **967** |
| **Net cash from (or used by) financing activities** | **(634)** | **(745)** | **(788)** | **(834)** | **(881)** |
| **Net increase (or decrease) in cash held** | **-** | **-** | **-** | **-** | **-** |
| Cash and cash equivalents at the beginning of the reporting period | 276 | 276 | 276 | 276 | 276 |
| **Cash and cash equivalents at the end of the reporting period** | **276** | **276** | **276** | **276** | **276** |

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

**Table 3.5: Departmental capital budget statement (for the period ended
30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2022–23 Estimated actual$'000** | **2023–24Budget$'000** | **2024–25Forward estimate$'000** | **2025–26Forward estimate$'000** | **2026–27Forward estimate$'000** |
| **CAPITAL APPROPRIATIONS** |   |   |  |   |   |
| Capital budget - Bill 1 (DCB) | 83 | 84 | 85 | 85 | 86 |
| **Total capital appropriations** | **83** | **84** | **85** | **85** | **86** |
| **Total new capital appropriations represented by:** |   |   |  |   |   |
| Purchase of non-financial assets | 83 | 84 | 85 | 85 | 86 |
| **Total represented by** | **83** | **84** | **85** | **85** | **86** |
| **PURCHASE OF NON-FINANCIAL ASSETS** |   |   |  |   |   |
| Funded by capital appropriation - DCB (a) | 83 | 84 | 85 | 85 | 86 |
| Funded internally from departmental resources | 184 | 8 | 8 | 197 | 75 |
| **Total acquisitions of non-financial assets** | **267** | **92** | **93** | **282** | **161** |
| **RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE** |  |   |  |  |  |
| Total purchases | 267 | 92 | 93 | 282 | 161 |
| **Total cash used to acquire assets** | **267** | **92** | **93** | **282** | **161** |

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

(a) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

**Table 3.6: Statement of departmental asset movements
(Budget year 2023–24)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Buildings $'000** | **Property, plant and equipment $'000** | **Intangibles $'000** | **Total $'000** |
| **As at 1 July 2023** |  |  |  |  |
| Gross book value  | 1,105 | 2,145 | 1,401 | **4,651** |
| Gross book value - RoU | 4,860 | - | - | **4,860** |
| Accumulated depreciation/amortisation and impairment | (414) | (1,881) | (1,215) | **(3,510)** |
| Accumulated depreciation/ amortisation and impairment - RoU | (1,699) | - | - | **(1,699)** |
| **Opening net book balance** | **3,852** | **264** | **186** | **4,302** |
| **CAPITAL ASSET ADDITIONS** |  |  |  |  |
| **Estimated expenditure on new or replacement assets** |  |  |  |  |
| Funded by capital appropriation - - DCB (a) | - | 76 | 8 | **84** |
| Funded internally from departmental resources | - | 8 | - | **8** |
| By purchase - RoU | - | - | - | **-** |
| **Total additions** | **-** | **84** | **8** | **92** |
| **Other movements** |  |  |  |  |
| Depreciation/amortisation expense | (172) | (192) | (92) | **(456)** |
| Depreciation/amortisation expense - RoU | (736) | - | - | **(736)** |
| **Total other movements** | **(908)** | **(192)** | **(92)** | **(1,192)** |
| **As at 30 June 2024** |  |  |  |  |
| Gross book value | 1,105 | 2,229 | 1,409 | **4,743** |
| Gross book value – RoU | 4,860 | - | - | **4,860** |
| Accumulated depreciation amortisation and impairment | (586) | (2,073) | (1,307) | **(3,966)** |
| Accumulated depreciation/ amortisation and impairment - RoU | (2,435) | - | - | **(2,435)** |
| **Closing net book balance** | **2,944** | **156** | **102** | **3,202** |

Prepared on Australian Accounting Standards basis.

DCB = Departmental Capital Budget

RoU = Right-of-Use asset

(a) Does not include annual finance lease costs. Includes purchases from current and previous years' DCB.

**Table 3.7: Schedule of budgeted income and expenses administered on behalf of Government (for the period ended 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | **2022–23 Estimated actual$'000** | **2023–24Budget$'000** | **2024–25Forward estimate$'000** | **2025–26Forward estimate$'000** | **2026–27Forward estimate$'000** |
| **EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |   |  |  |  |
| Grants | 13,028 | 14,376 | 21,800 | 23,207 | 23,088 |
| Suppliers | 5,595 | 10,367 | 12,562 | 10,090 | 10,300 |
| **Total expenses administered on behalf of Government** | **18,623** | **24,743** | **34,362** | **33,297** | **33,388** |
| **INCOME ADMINISTERED ON BEHALF OF GOVERNMENT** |  |   |  |  |  |
| **Revenue** |  |   |  |  |  |
| **Non-taxation** |  |   |  |  |  |
| Other non-tax revenue | - | - | - | - | - |
| **Total non-taxation revenue** | **-** | **-** | **-** | **-** | **-** |
| **Total revenues administered on behalf of Government** | **-** | **-** | **-** | **-** | **-** |
| **Total income administered on behalf of Government** | **-** | **-** | **-** | **-** | **-** |

Prepared on Australian Accounting Standards basis.

**Table 3.8: Schedule of budgeted assets and liabilities administered on behalf of Government (as at 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | **2022–23 Estimated actual$'000** | **2023–24Budget$'000** | **2024–25Forward estimate$'000** | **2025–26Forward estimate$'000** | **2026–27Forward estimate$'000** |
| **ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT** |  |   |  |  |  |
| **Financial assets** |  |   |  |  |  |
| Cash and cash equivalents | 34 | 34 | 34 | 34 | 34 |
| Receivables | 416 | 416 | 416 | 416 | 416 |
| **Total financial assets** | **450** | **450** | **450** | **450** | **450** |
| **Non financial assets** |  |   |  |  |  |
| Prepayments | 11 | 11 | 11 | 11 | 11 |
| **Total financial assets** | **11** | **11** | **11** | **11** | **11** |
| **Total assets administered on behalf of Government** | **461** | **461** | **461** | **461** | **461** |
| **LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT** |  |   |  |  |  |
| **Payables** |  |   |  |  |  |
| Suppliers | 812 | 812 | 812 | 812 | 812 |
| Grants | 2,876 | 2,876 | 2,876 | 2,876 | 2,876 |
| **Total payables** | **3,688** | **3,688** | **3,688** | **3,688** | **3,688** |
| **Total liabilities administered on behalf of Government** | **3,688** | **3,688** | **3,688** | **3,688** | **3,688** |

Prepared on Australian Accounting Standards basis.

**Table 3.9: Schedule of budgeted administered cash flows (for the period ended 30 June)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|   | **2022–23 Estimated actual$'000** | **2023–24Budget$'000** | **2024–25Forward estimate$'000** | **2025–26Forward estimate$'000** | **2026–27Forward estimate$'000** |
| **OPERATING ACTIVITIES** |  |   |  |  |  |
| **Cash received** |  |   |  |  |  |
| Net GST received | 617 | 617 | 624 | 624 | 624 |
| Other | - | - | - | - | - |
| **Total cash received** | **617** | **617** | **624** | **624** | **624** |
| **Cash used** |  |   |  |  |  |
| Grant payments | 13,119 | 14,467 | 21,892 | 23,299 | 23,180 |
| Suppliers | 6,121 | 10,893 | 13,094 | 10,622 | 10,832 |
| **Total cash used** | **19,240** | **25,360** | **34,986** | **33,921** | **34,012** |
| **Net cash from (or used by) operating activities** | **(18,623)** | **(24,743)** | **(34,362)** | **(33,297)** | **(33,388)** |
| **Net increase (or decrease) in cash held** | **(18,623)** | **(24,743)** | **(34,362)** | **(33,297)** | **(33,388)** |
| Cash at beginning of reporting period | 34 | 34 | 34 | 34 | 34 |
| Cash from the OPA for: |  |   |  |  |  |
| - appropriations | 18,623 | 24,743 | 34,362 | 33,297 | 33,388 |
| - GST | 617 | 617 | 624 | 624 | 624 |
| Cash to the OPA |  |   |  |  |  |
| - return of GST | (617) | (617) | (624) | (624) | (624) |
| - other | - | - | - | - | - |
| **Cash at end of reporting period** | **34** | **34** | **34** | **34** | **34** |

Prepared on Australian Accounting Standards basis.

OPA = Official Public Account

1. For more information about the strategic direction of Cancer Australia, refer to the current Corporate Plan, available at: www.canceraustralia.gov.au/about-us/accountability-and-reporting [↑](#footnote-ref-1)